Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Tuberculosis, Pulmonary Clinical Trials

11 recruiting trials for Tuberculosis, Pulmonary. Eligibility criteria explained in plain English.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
11
Total Trials
11
Recruiting Now
1
Phase 3 Trials
10
Sponsors

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGPhase 2 / Phase 3NCT04147286

Atorvastatin to Reduce Inflammation After Tuberculosis Treatment Completion

This is a proof-of-concept phase IIB, double-blind, randomized, placebo-controlled trial to evaluate the safety and efficacy of 40 mg atorvastatin to reduce persistent lung...

Sponsor: University of Cape TownEnrolling: 2201 location
RECRUITINGPhase 3NCT06253715

Shortened Regimen for Drug-susceptible TB in Children

While drug-susceptible tuberculosis (TB) disease in children currently requires four to six months of treatment, most children may be able to be cured with a shorter treatment of...

Sponsor: Johns Hopkins UniversityEnrolling: 8609 locations
RECRUITINGNCT07077213

18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) in Tuberculosis Patients

The investigators will assess the hypothesis is that 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) Positron emission tomography (PET) could be used as a noninvasive...

Sponsor: Children's Hospital Medical Center, CincinnatiEnrolling: 301 location
RECRUITINGNCT05285202

Clinic-based Versus Hotspot-focused Active TB Case Finding

This five-year study will evaluate two strategies for conducting tuberculosis (TB) active case finding (ACF) and linkage to TB treatment or TB preventive therapy (TPT) in...

Sponsor: Johns Hopkins UniversityEnrolling: 1500001 location
RECRUITINGNCT05756582

Prevalence of Latent Tuberculosis Infection in Health-care Workers and Students

This study is a cross-sectional study that examines the prevalence of Latent Tuberculosis Infection \[LTBI\], defined as individuals infected with Mycobacterium tuberculosis with...

Sponsor: Eleonora NuceraEnrolling: 20401 location
RECRUITINGNCT06585358

DoseTB-individualised Dosing by Model-informed Precision Dosing for Pulmonary Tuberculosis

The goal of this observational study is to investigate whether model-informed precision dosing (MIPD), as a clinical support for early individualised dosing in addition to the...

Sponsor: Karolinska InstitutetEnrolling: 302 locations
RECRUITINGNCT07271225

Safety and Efficacy of Ear Acupuncture for Antituberculosis Drug-Related Nausea and Vomiting

This study will look at whether press-needle ear acupuncture can help lower nausea and vomiting caused by antituberculosis medicines in people with pulmonary tuberculosis. Nausea...

Sponsor: Indonesia UniversityEnrolling: 581 location
RECRUITINGNCT06159023

Conventional Bronchoscope With BAL vs. Thin Bronchoscope With BW to Diagnose Pulmonary TB

This study aims to compare the diagnostic yield of bronchoalveolar lavage (BAL) using a thick conventional bronchoscope and bronchial washing (BW) using a thin bronchoscope in the...

Sponsor: Pusan National University HospitalEnrolling: 1321 location
RECRUITINGNCT05539014

Tuberculosis Cohort Avicenne Hospital

Tuberculosis represents the second highest death rate from an infectious disease in the world, just after COVID-19. The most affected department of France is Seine-Saint-Denis....

Sponsor: Assistance Publique - Hôpitaux de ParisEnrolling: 2502 locations
RECRUITINGNCT06706596

A Systemic Screening for TB Disease in High-risk Groups in Barcelona

The purpose of this screening study is to identify and screen vulnerable population in Barcelona for active pulmonary tuberculosis

Sponsor: Fundació Institut Germans Trias i PujolEnrolling: 30001 location
RECRUITINGPhase 2 / Phase 3NCT06441006

Program for Rifampicin-Resistant Disease With Stratified Medicine for Tuberculosis

PRISM-TB is an international, seamless, multicenter, open-label, randomized, controlled, pragmatic, stratified medicine, treatment shortening, multi-arm multi-stage (MAMS),...

Sponsor: University of California, San FranciscoEnrolling: 4006 locations

Frequently Asked Questions

There are currently 11 clinical trials for Tuberculosis, Pulmonary, with 11 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Tuberculosis, Pulmonary, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 1 Phase 3 trials for Tuberculosis, Pulmonary, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice — always talk to your doctor about clinical trial participation.